Molecular profiling in breast cancer
Open Access
- 27 April 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Reviews in Endocrine and Metabolic Disorders
- Vol. 8 (3), 185-198
- https://doi.org/10.1007/s11154-007-9035-3
Abstract
Molecular profiling has provided biological evidence for the heterogeneity of breast cancer through the identification of intrinsic subtypes like Luminal A, Luminal B, HER2+/ER- and basal-like. It has also led to the development of clinically applicable gene expression-based prognostic panels like the Mammaprint and Oncotype Dx. The increasingly sophisticated understanding allowed by this and similar technology promises future individualized therapy.Keywords
This publication has 79 references indexed in Scilit:
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- Concordance among Gene-Expression–Based Predictors for Breast CancerThe New England Journal of Medicine, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002